Sofosbuvir and Ribavirin Therapy for Children Aged 3 to <12 Years With Hepatitis C Virus Genotype 2 or 3 Infection

Currently, the only approved hepatitis C virus (HCV) treatment for children aged <12 years is pegylated interferon plus ribavirin. In an open‐label study, we evaluated the safety and efficacy of sofosbuvir plus ribavirin for 12 weeks in children aged 3 to <12 years chronically infected with ge...

Descripción completa

Detalles Bibliográficos
Autores principales: Rosenthal, Philip, Schwarz, Kathleen B., Gonzalez‐Peralta, Regino P., Lin, Chuan‐Hao, Kelly, Deidre A., Nightingale, Scott, Balistreri, William F., Bansal, Sanjay, Jonas, Maureen M., Massetto, Benedetta, Brainard, Diana M., Hsueh, Chia‐Hsiang, Shao, Jiang, Parhy, Bandita, Davison, Suzanne, Feiterna‐Sperling, Cornelia, Gillis, Lynette A., Indolfi, Giuseppe, Sokal, Etienne M., Murray, Karen F., Wirth, Stefan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7004103/
https://www.ncbi.nlm.nih.gov/pubmed/31222783
http://dx.doi.org/10.1002/hep.30821

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7004103/
https://www.ncbi.nlm.nih.gov/pubmed/31222783
http://dx.doi.org/10.1002/hep.30821

Ejemplares similares